Literature DB >> 20936745

Meta-analysis and moderation.

.   

Abstract

Mesh:

Substances:

Year:  2010        PMID: 20936745     DOI: 10.1038/nrd3294

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

1.  The safety of tiotropium--the FDA's conclusions.

Authors:  Theresa M Michele; Simone Pinheiro; Solomon Iyasu
Journal:  N Engl J Med       Date:  2010-09-08       Impact factor: 91.245

Review 2.  Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Sonal Singh; Yoon K Loke; Curt D Furberg
Journal:  JAMA       Date:  2008-09-24       Impact factor: 56.272

3.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease.

Authors:  Donald P Tashkin; Bartolome Celli; Stephen Senn; Deborah Burkhart; Steven Kesten; Shailendra Menjoge; Marc Decramer
Journal:  N Engl J Med       Date:  2008-10-05       Impact factor: 91.245

4.  Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Authors:  Philip D Home; Stuart J Pocock; Henning Beck-Nielsen; Paula S Curtis; Ramon Gomis; Markolf Hanefeld; Nigel P Jones; Michel Komajda; John J V McMurray
Journal:  Lancet       Date:  2009-06-06       Impact factor: 79.321

5.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

  5 in total
  1 in total

1.  Meta-analysis of chicken--salmonella infection experiments.

Authors:  Marinus F W Te Pas; Ina Hulsegge; Dirkjan Schokker; Mari A Smits; Mark Fife; Rima Zoorob; Marie-Laure Endale; Johanna M J Rebel
Journal:  BMC Genomics       Date:  2012-04-24       Impact factor: 3.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.